Tumor recurrence after pathological complete response in locally advanced gastric cancer after neoadjuvant therapy:
Yu Xing1,2,3, Zi-Li Zhang1,2,3, Zhi-Ying Ding1,2,3
1Department of Surgery, The Third Central Clinical College of Tianjin Medical University, Tianjin 300170, China.
Background:
The pathological complete response (ypCR) rate following neoadjuvant chemotherapy for advanced gastric cancer remains low and lacks a universally accepted treatment protocol. Immunotherapy has achieved breakthrough progress.
Case Summary:
We report two female patients with gastric cancer defined as clinical stage cT4N1-2M0. Detection of mismatch repair protein showed mismatch repair function defect, and perioperative treatment with programmed death protein 1 inhibitor combined with S-1+oxaliplatin achieved ypCR. Surprisingly, the patients underwent clinical observation after surgery but developed different degrees of metastasis at ~6 mo after surgery.
Conclusion:
PD-1 inhibitor combined with chemotherapy provides a more strategic choice for comprehensive perioperative treatment of gastric cancer.
